‘Pay for delay’: privity and Lundbeck
Pharmaceuticals company Lundbeck has been the subject of two important decisions in recent weeks — the first concerning the practice of pharmaceuticals companies seeking to prevent or delay the entry onto the market of generic competitors and the second relating to privity of interest in a patent dispute. The European Commission has been investigating perceived anti-competitive […]